<p>股息股票因多種原因成為了很好的投資選擇。在價格下跌時買入更是不錯，當然，前提是它們有能力反彈。</p>
<p>尋找符合這一特徵的公司的投資者應當強烈考慮 <strong>輝瑞</strong>（PFE 0.22%）和 <strong>默克</strong>（MRK 1.86%）。這兩家市場領導者在過去 12 個月的表現落後於大盤，但對於那些關注長期投資的人來説，它們仍然看起來具有吸引力。以下是詳細情況。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1MzQvcGh5c2ljaWFuLWdpdmluZy1tZWRpY2luZS10by1lbGRlcmx5LXBhdGllbnQuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1MzQvcGh5c2ljaWFuLWdpdmluZy1tZWRpY2luZS10by1lbGRlcmx5LXBhdGllbnQuanBnJnc9NzAw"/></p>
<p>圖片來源：Getty Images。</p>
<h2>1. 輝瑞</h2>
<p>在過去幾年中，輝瑞面臨着財務結果惡化和某些產品競爭加劇的問題。它還面臨失去其他產品專利保護的前景；這些產品包括 Eliquis，一種抗凝藥，是其暢銷藥物之一，以及 Xtandi，一種癌症治療藥物。這兩種藥物將在未來幾年內在美國失去專利。</p>
<p>這些挑戰導致了糟糕的股市表現。然而，拋售可能已經過度。在當前水平下，輝瑞的股票看起來具有吸引力。</p>
<p>公司能夠反彈並在長期內繼續提供強勁回報的一個原因是其豐富的產品管線，特別是在腫瘤學領域，這是行業中最大的治療領域之一。輝瑞目前擁有五種重磅癌症藥物，並計劃到 2030 年將這一數字提高到八種。</p>
<p>輝瑞在其他領域也有令人興奮的候選藥物，近年來獲得了幾種新產品的批准。儘管這些產品尚未對其收入增長產生顯著貢獻，但隨着它們獲得標籤擴展，最終應該會有所貢獻。</p>
<p>該公司的呼吸道合胞病毒（RSV）疫苗 Abrysvo 在第二季度產生了 1.43 億美元的銷售額，這對於一款在 2023 年獲得批准的產品來説並不算差。它最近還在歐洲獲得了針對 18 至 59 歲成人的標籤擴展（之前僅適用於 60 歲及以上人羣）。輝瑞應該會在 Abrysvo 和其他新產品的推出上取得進展。</p>
<p>公司還在減少開支。這些舉措可能部分導致輝瑞在第二季度的盈利超出預期。管理層計劃在今年實現 45 億美元的淨成本節約，並在未來幾年繼續追求進一步的減少，這些努力應該有助於提高盈利能力。</p>
<p>輝瑞是一隻穩健的股息股票。其前瞻性收益率目前超過 7%，公司在過去五年中增加了 19.5% 的分紅。儘管股票可能需要一些時間才能恢復，但輝瑞可能是尋求收入的投資者的優秀長期投資。</p>
<h2>2. 默克</h2>
<p>默克面臨幾個問題，其中最重要的是其暢銷藥物癌症藥物 Keytruda 的競爭加劇，以及該藥物在 2028 年即將到來的專利懸崖。此外，公司的第二季度業績也不強勁：收入同比下降 2%，至 158 億美元，而調整後的每股收益下降 7%，至 2.13 美元。</p>
<p>然而，公司也有一些亮點。最顯著的是，Winrevair——其最新推出的藥物之一，去年獲得批准——報告銷售額為 3.36 億美元。Winrevair 是一種用於肺動脈高壓的新機制治療藥物，預計很快將成為重磅藥物。</p>
<p>默克在動物健康領域的業務表現也很好，該領域是其領導者之一，第二季度該細分市場的銷售額同比增長 11%，達到 16 億美元。</p>
<p>與此同時，默克有一些令人興奮的產品管線候選藥物，應該能幫助其克服與 Keytruda 相關的挑戰。其中之一是 Keytruda 的皮下給藥版本，已經通過了三期研究，將有助於延長該藥物的專利保護。近年來，默克通過許可協議顯著改善了其產品管線。其候選藥物包括有前景的癌症產品和減肥藥物。</p>
<p>正如 Winrevair 似乎是一個重大成功，默克也可能開發出創新療法，以減輕潛在的 Keytruda 相關收入損失。因此，儘管最近遭遇挫折，但考慮到默克的創新歷史，該業務可能會反彈。</p>
<p>談到默克的股息計劃，該公司目前提供 4.1% 的前瞻性收益率，過去五年中其股息增長了 39%。該股票仍然是股息投資者的良好選擇。</p>

輝瑞

默克

<p>投資者被鼓勵考慮輝瑞和默克作為在市場回調時值得購買的頂級分紅股票。儘管輝瑞面臨專利到期和競爭等挑戰，但其在腫瘤學領域擁有強大的產品線，預期收益率超過 7%。默克雖然在其藥物 Keytruda 面臨競爭，但也有前景良好的新產品，預期收益率為 4.1%。過去五年中，這兩家公司都大幅提高了分紅，使其成為尋求收入的投資者的吸引選項</p>

<p>Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back.</p>
<div class="lb-trans"><p>股息股票因多種原因成為了很好的投資選擇。在價格下跌時買入更是不錯，當然，前提是它們有能力反彈。</p>
</div><p>Investors looking for companies that fit this profile should strongly consider <strong>Pfizer</strong>(PFE 0.22%) and <strong>Merck</strong>(MRK 1.86%). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown.</p>
<div class="lb-trans"><p>尋找符合這一特徵的公司的投資者應當強烈考慮 <strong>輝瑞</strong>（PFE 0.22%）和 <strong>默克</strong>（MRK 1.86%）。這兩家市場領導者在過去 12 個月的表現落後於大盤，但對於那些關注長期投資的人來説，它們仍然看起來具有吸引力。以下是詳細情況。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1MzQvcGh5c2ljaWFuLWdpdmluZy1tZWRpY2luZS10by1lbGRlcmx5LXBhdGllbnQuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F828534%2Fphysician-giving-medicine-to-elderly-patient.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>圖片來源：Getty Images。</p>
</div><h2>1. Pfizer</h2>
<div class="lb-trans"><h2>1. 輝瑞</h2>
</div><p>Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years.</p>
<div class="lb-trans"><p>在過去幾年中，輝瑞面臨着財務結果惡化和某些產品競爭加劇的問題。它還面臨失去其他產品專利保護的前景；這些產品包括 Eliquis，一種抗凝藥，是其暢銷藥物之一，以及 Xtandi，一種癌症治療藥物。這兩種藥物將在未來幾年內在美國失去專利。</p>
</div><p>These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive.</p>
<div class="lb-trans"><p>這些挑戰導致了糟糕的股市表現。然而，拋售可能已經過度。在當前水平下，輝瑞的股票看起來具有吸引力。</p>
</div><p>One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030.</p>
<div class="lb-trans"><p>公司能夠反彈並在長期內繼續提供強勁回報的一個原因是其豐富的產品管線，特別是在腫瘤學領域，這是行業中最大的治療領域之一。輝瑞目前擁有五種重磅癌症藥物，並計劃到 2030 年將這一數字提高到八種。</p>
</div><p>Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion.</p>
<div class="lb-trans"><p>輝瑞在其他領域也有令人興奮的候選藥物，近年來獲得了幾種新產品的批准。儘管這些產品尚未對其收入增長產生顯著貢獻，但隨着它們獲得標籤擴展，最終應該會有所貢獻。</p>
</div><p>The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches.</p>
<div class="lb-trans"><p>該公司的呼吸道合胞病毒（RSV）疫苗 Abrysvo 在第二季度產生了 1.43 億美元的銷售額，這對於一款在 2023 年獲得批准的產品來説並不算差。它最近還在歐洲獲得了針對 18 至 59 歲成人的標籤擴展（之前僅適用於 60 歲及以上人羣）。輝瑞應該會在 Abrysvo 和其他新產品的推出上取得進展。</p>
</div><p>The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability.</p>
<div class="lb-trans"><p>公司還在減少開支。這些舉措可能部分導致輝瑞在第二季度的盈利超出預期。管理層計劃在今年實現 45 億美元的淨成本節約，並在未來幾年繼續追求進一步的減少，這些努力應該有助於提高盈利能力。</p>
</div><p>Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors.</p>
<div class="lb-trans"><p>輝瑞是一隻穩健的股息股票。其前瞻性收益率目前超過 7%，公司在過去五年中增加了 19.5% 的分紅。儘管股票可能需要一些時間才能恢復，但輝瑞可能是尋求收入的投資者的優秀長期投資。</p>
</div><h2>2. Merck</h2>
<div class="lb-trans"><h2>2. 默克</h2>
</div><p>Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13.</p>
<div class="lb-trans"><p>默克面臨幾個問題，其中最重要的是其暢銷藥物癌症藥物 Keytruda 的競爭加劇，以及該藥物在 2028 年即將到來的專利懸崖。此外，公司的第二季度業績也不強勁：收入同比下降 2%，至 158 億美元，而調整後的每股收益下降 7%，至 2.13 美元。</p>
</div><p>However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon.</p>
<div class="lb-trans"><p>然而，公司也有一些亮點。最顯著的是，Winrevair——其最新推出的藥物之一，去年獲得批准——報告銷售額為 3.36 億美元。Winrevair 是一種用於肺動脈高壓的新機制治療藥物，預計很快將成為重磅藥物。</p>
</div><p>Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter.</p>
<div class="lb-trans"><p>默克在動物健康領域的業務表現也很好，該領域是其領導者之一，第二季度該細分市場的銷售額同比增長 11%，達到 16 億美元。</p>
</div><p>Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines.</p>
<div class="lb-trans"><p>與此同時，默克有一些令人興奮的產品管線候選藥物，應該能幫助其克服與 Keytruda 相關的挑戰。其中之一是 Keytruda 的皮下給藥版本，已經通過了三期研究，將有助於延長該藥物的專利保護。近年來，默克通過許可協議顯著改善了其產品管線。其候選藥物包括有前景的癌症產品和減肥藥物。</p>
</div><p>Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation.</p>
<div class="lb-trans"><p>正如 Winrevair 似乎是一個重大成功，默克也可能開發出創新療法，以減輕潛在的 Keytruda 相關收入損失。因此，儘管最近遭遇挫折，但考慮到默克的創新歷史，該業務可能會反彈。</p>
</div><p>Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers.</p>
<div class="lb-trans"><p>談到默克的股息計劃，該公司目前提供 4.1% 的前瞻性收益率，過去五年中其股息增長了 39%。該股票仍然是股息投資者的良好選擇。</p>
</div>

2 Top Dividend Stocks to Buy on the Dip

- 辛普森和默克是值得關注的股息股票，儘管面臨挑戰。  
- 辛普森的深厚藥物管線和成本節約措施有助於其長期回報。  
- 默克的新藥 Winrevair 和創新療法可能緩解 Keytruda 的競爭壓力。

兩隻在股價回調時值得買入的頂級股息股票